Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
ORGANIZATION
PhRMA Japan Chief Laments CEA Expansion, Calls for Sweeping Reform
The decision to expand Japan’s cost-effectiveness assessment (CEA) system is “deeply disappointing” and risks eroding confidence in the government’s growth strategy, a US pharma industry leader said, pressing for drastic drug pricing reforms to counter the US most-favored-nation (MFN) policy.…
To read the full story
Related Article
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- Chuikyo OKs Tougher CEA Price Cuts for Drugs Tagged “Cost Increase”
November 12, 2026
- Chuikyo Weighs “Agile Response” to MFN as Providers Question Drug Lag, Loss Impact
November 12, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- PhRMA Welcomes Honebuto, Prods Japan to Launch Reform This Year
July 22, 2026
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
ORGANIZATION
- PhRMA Japan Chief Laments CEA Expansion, Calls for Sweeping Reform
November 20, 2026
- JPMA, EFPIA Follow PhRMA in Decrying CEA Price Cut Expansion
November 19, 2026
- PhRMA Slams CEA Expansion, Warns It Undermines Japan Growth Strategy
November 17, 2026
- UCB Japan President Kikuchi to Take Helm of EFPIA Japan
November 13, 2026
- Japan Pharmacy Group Renews Call to Scrap Off-Year Drug Price Revisions
November 13, 2026





